9MW-0311 is under clinical development by Mabwell Shanghai Bioscience and currently in Phase III for Diabetes. According to GlobalData, Phase III drugs for Diabetes have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how 9MW-0311’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

9MW-0311 overview

Denosumab biosimilar is under development for the treatment of diabetes and osteoporosis. It is administered as injection. The therapeutic candidate acts by targeting receptor activator of nuclear factor kappa B ligand (RANKL).

Mabwell Shanghai Bioscience overview

Mabwell Shanghai Bioscience is a company that is focused on the discovery and industrialization of therapeutic monoclonal antibody, innovative vaccines and long-acting cytokine drugs. The company is headquartered in Shanghai, China.

For a complete picture of 9MW-0311’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.